Trials / Active Not Recruiting
Active Not RecruitingNCT06555796
Evaluation of Xaluritamig in High-Risk, Biochemically Recurrent, Non-metastatic Castrate-sensitive Prostate Cancer
A Phase 1b, Open-label, Multicenter Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Subjects With High-risk Biochemical Recurrence of Nonmetastatic Castration-sensitive Prostate Cancer After Definitive Therapy
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 50 (actual)
- Sponsor
- Amgen · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main objective of this study is to evaluate the safety and tolerability of xaluritamig monotherapy in adult participants with high-risk biochemical recurrent (BCR) nonmetastatic castration-sensitive prostate cancer (nmCSPC).
Conditions
- Prostate Cancer
- High-risk Biochemical Recurrence
- High Risk Biochemical Recurrence of Non-metastatic Castration-sensitive Prostate Cancer
- Non-metastatic Castration-sensitive Prostate Cancer
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Xaluritamig | IV infusion |
Timeline
- Start date
- 2024-09-23
- Primary completion
- 2026-10-08
- Completion
- 2028-12-02
- First posted
- 2024-08-15
- Last updated
- 2026-01-26
Locations
11 sites across 2 countries: United States, Australia
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06555796. Inclusion in this directory is not an endorsement.